Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Skin Cancer01:30

Skin Cancer

Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pediatric emergency backpacks-effects of using xABCDE- and Broselow-systems on pediatric emergency care.

European journal of pediatrics·2025
Same author

Metachronous primary secretory carcinomas of the eyelid and the parotid gland.

Journal of cutaneous pathology·2023
Same author

[Infiltration of the skull by dedifferentiated cutaneous leiomyosarcoma].

Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete·2021
Same author

[Subcutaneous nodule on the lower leg of an 87-year-old man].

Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete·2021
Same author

[Digital papillary adenocarcinoma : Four case reports with brief literature review].

Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete·2018
Same author

An enlarging pedunculated nodule on the shoulder of a 21-year-old man.

Clinical and experimental dermatology·2018
Same journal

TFE3-rearranged PEComa with hepatic and pulmonary involvement: diagnostic challenges and resistance to mTOR-targeted therapy.

Journal of cancer research and clinical oncology·2026
Same journal

GALNT5 drives colorectal cancer progression and chemoresistance via PI3K/Akt/ABCC1 axis.

Journal of cancer research and clinical oncology·2026
Same journal

Editorial Expression of Concern: Frequent inactivation of RUNX3 by promoter hypermethylation and protein mislocalization in oral squamous cell carcinomas.

Journal of cancer research and clinical oncology·2026
Same journal

Nano-biosensors for circulating tumor markers: advancing liquid biopsy toward precision cancer diagnostics.

Journal of cancer research and clinical oncology·2026
Same journal

Predictive value of folate receptor-positive circulating tumor cells in postoperative progressive disease of non-small cell lung cancer patients.

Journal of cancer research and clinical oncology·2026
Same journal

Stained region lymph node biopsy for axillary restaging after neoadjuvant systemic therapy in node-positive breast cancer: a cohort study.

Journal of cancer research and clinical oncology·2026
See all related articles

Related Experiment Video

Updated: Jun 25, 2026

Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis
06:59

Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis

Published on: August 26, 2025

Current treatment options in dermatofibrosarcoma protuberans.

Doreen Lemm1, L-O Mügge, T Mentzel

  • 1Hämatologie/Onkologie, Klinik für Innere Medizin II, Universitätsklinikum Jena, Jena, Germany, doreen.lemm@med.uni-jena.de

Journal of Cancer Research and Clinical Oncology
|February 12, 2009
PubMed
Summary
This summary is machine-generated.

Dermatofibrosarcoma protuberans (DFSP) is a rare skin cancer. Complete surgical resection with wide margins is the primary treatment, with Mohs surgery reducing recurrence.

Related Experiment Videos

Last Updated: Jun 25, 2026

Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis
06:59

Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis

Published on: August 26, 2025

Area of Science:

  • Oncology
  • Dermatology
  • Genetics

Background:

  • Dermatofibrosarcoma protuberans (DFSP) is a rare malignant dermal neoplasm.
  • DFSP exhibits slow infiltrative growth, low metastatic potential, but high local recurrence rates post-excision.

Purpose of the Study:

  • To review current opinions and literature on Dermatofibrosarcoma protuberans (DFSP).
  • To discuss resulting therapeutic strategies for DFSP.

Main Methods:

  • Literature review of current opinions and therapeutic strategies for DFSP.
  • Analysis of treatment outcomes related to surgical resection extent and targeted therapies.

Main Results:

  • Complete surgical resection with wide margins is the optimal therapy for DFSP.
  • Mohs micrographic surgery can reduce local recurrence rates.
  • Targeted inhibitors of platelet-derived growth factor receptor (PDGFR) show promise for unresectable or metastatic DFSP.

Conclusions:

  • Complete surgical resection is crucial for high cure rates in DFSP.
  • Targeted PDGFR inhibition offers a therapeutic option for advanced or recurrent DFSP.
  • Further research into DFSP treatment strategies is warranted.